Wockhardt Reports Q1 FY27 PAT of ₹107 Cr, Revenue Up 26%
Wockhardt Limited announced its unaudited financial results for the first quarter of FY27, reporting a Profit After Tax (PAT) of ₹107 crore, a significant turnaround from a loss in the previous year. The company's revenue for the quarter stood at ₹929 crore, marking a 26% year-on-year increase. EBITDA also saw a substantial growth of 86%, reaching ₹188 crore. The biotech operations demonstrated strong performance with a 112% growth, driven by emerging markets. Regionally, Emerging Markets, UK, and Ireland showed robust revenue growth, while the India Branded Business grew by 21%. The company also highlighted progress in new product launches and regulatory approvals, including the US FDA approval for the novel antibiotic Zaynich®.
Key Highlights
- Q1 FY27 PAT at ₹107 Cr, a significant improvement from the prior year.
- Revenue grew 26% YoY to ₹929 Cr in Q1 FY27.
- EBITDA surged 86% YoY to ₹188 Cr in Q1 FY27.
- Biotech operations grew 112% YoY, driven by emerging markets.
- Zaynich® received US FDA approval for cUTI treatment.
Price Impact
More from WOCKPHARMA